ATE315558T1 - Verbindungen mit cytochrom p450ra1 hemmenden aktivität - Google Patents

Verbindungen mit cytochrom p450ra1 hemmenden aktivität

Info

Publication number
ATE315558T1
ATE315558T1 AT01965920T AT01965920T ATE315558T1 AT E315558 T1 ATE315558 T1 AT E315558T1 AT 01965920 T AT01965920 T AT 01965920T AT 01965920 T AT01965920 T AT 01965920T AT E315558 T1 ATE315558 T1 AT E315558T1
Authority
AT
Austria
Prior art keywords
compounds
cytochrome
p450ra1
inhibitive activity
inhibitive
Prior art date
Application number
AT01965920T
Other languages
German (de)
English (en)
Inventor
Jayasree Vasudevan
Alan T Johnson
Dehua Huang
Liming Wang
Roshantha A Chandraratna
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/651,234 external-priority patent/US6387951B1/en
Priority claimed from US09/651,235 external-priority patent/US6252090B1/en
Priority claimed from US09/651,001 external-priority patent/US6291677B1/en
Priority claimed from US09/651,564 external-priority patent/US6380256B1/en
Priority claimed from US09/651,003 external-priority patent/US6303785B1/en
Priority claimed from US09/651,566 external-priority patent/US6369225B1/en
Priority claimed from US09/651,004 external-priority patent/US6369261B1/en
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE315558T1 publication Critical patent/ATE315558T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
AT01965920T 2000-08-29 2001-08-14 Verbindungen mit cytochrom p450ra1 hemmenden aktivität ATE315558T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/651,234 US6387951B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,235 US6252090B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,001 US6291677B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,564 US6380256B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,003 US6303785B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,566 US6369225B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI
US09/651,004 US6369261B1 (en) 2000-08-29 2000-08-29 Compounds having activity as inhibitors of cytochrome P450RAI

Publications (1)

Publication Number Publication Date
ATE315558T1 true ATE315558T1 (de) 2006-02-15

Family

ID=27569871

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01965920T ATE315558T1 (de) 2000-08-29 2001-08-14 Verbindungen mit cytochrom p450ra1 hemmenden aktivität

Country Status (8)

Country Link
EP (1) EP1366036B1 (cg-RX-API-DMAC10.html)
JP (1) JP2004507531A (cg-RX-API-DMAC10.html)
AT (1) ATE315558T1 (cg-RX-API-DMAC10.html)
AU (2) AU2001286471B2 (cg-RX-API-DMAC10.html)
CA (1) CA2420869A1 (cg-RX-API-DMAC10.html)
DE (1) DE60116642T2 (cg-RX-API-DMAC10.html)
ES (1) ES2256288T3 (cg-RX-API-DMAC10.html)
WO (1) WO2002018361A2 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313107B1 (en) * 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US6740676B2 (en) * 2002-03-19 2004-05-25 Allergan, Inc. 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
AU2004268455B2 (en) 2003-08-29 2009-12-17 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US7226951B2 (en) * 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
CA2591399C (en) 2004-12-13 2014-05-20 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medicinal use thereof
CA2589363A1 (en) 2004-12-13 2006-06-22 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
BRPI0608553A2 (pt) 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
BR112013012836A2 (pt) * 2010-11-24 2019-09-24 Allergan Inc moduladores dos receptores s1p"
JP2014527083A (ja) 2011-09-15 2014-10-09 アリゾナ ボード オブ リージェンツ， ア ボディー コーポレイト オブ ザ ステート オブ アリゾナ， アクティング フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティー 治療用化合物
WO2015109318A2 (en) 2014-01-17 2015-07-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Therapeutic methods
WO2016055800A2 (en) * 2014-10-10 2016-04-14 High Force Research Limited Fluorescent synthetic retinoids
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3475305D1 (en) * 1983-07-05 1988-12-29 Pfizer Carboxylic acid derivatives useful for inhibiting the degradation of cartilage
JPS6323868A (ja) * 1986-07-11 1988-02-01 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー アンギオテンシン２受容体遮断性イミダゾ−ル
US5089509A (en) * 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5015658A (en) * 1988-06-29 1991-05-14 Allergan, Inc. Thiochroman esters of phenols and terephthallates having retinoid-like activity
US5045551A (en) * 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5023341A (en) * 1989-09-19 1991-06-11 Allergan, Inc. Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US5202471A (en) * 1990-02-06 1993-04-13 Allergan, Inc. Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity
US5134159A (en) * 1991-03-26 1992-07-28 Allergan, Inc. 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
US5489584A (en) * 1994-12-29 1996-02-06 Allergan, Inc. Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
AU698527B2 (en) * 1994-12-29 1998-10-29 Allergan, Inc. Acetylenes disubstituted with a 5 or 8 substituted tetrahydronaphthyl or dihydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity

Also Published As

Publication number Publication date
EP1366036A2 (en) 2003-12-03
WO2002018361A3 (en) 2003-07-31
CA2420869A1 (en) 2002-03-07
AU2001286471B2 (en) 2006-09-07
HK1059439A1 (en) 2004-07-02
JP2004507531A (ja) 2004-03-11
DE60116642D1 (de) 2006-04-06
WO2002018361A2 (en) 2002-03-07
ES2256288T3 (es) 2006-07-16
EP1366036B1 (en) 2006-01-11
AU8647101A (en) 2002-03-13
DE60116642T2 (de) 2006-11-09

Similar Documents

Publication Publication Date Title
DE60116642D1 (de) Verbindungen mit cytochrom p450ra1 hemmenden aktivität
WO2002026727A3 (en) Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai
DE50014190D1 (de) Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten
EP1549767A4 (en) MODULATION OF EXPRESSION OF FORKHEAD BOX O1A
ATE411399T1 (de) Behandlung der huntington's krankheit mit epa
NO20002440L (no) Hydroksam- og karboksylsyrederivater med MMP- og TNF- inhiberende aktivitet
ATE395052T1 (de) Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
DE60312031D1 (de) Hydroxyethylamin-derivate für die behandlung von alzheimer
DK1301201T3 (da) Behandling af glycogenosis type II
ID24398A (id) Metode untuk menghasilkan asam l-amino
DE60219595D1 (de) Verfahren zur behandlung von erkrankungen mit malonyl coa-decarboxylase-inhibitoren
AU9536898A (en) 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the holesterin-ester transfer protein
BRPI0415773A (pt) derivados de indolinona e sua aplicação no tratamento de estados de doença tais como cáncer
DE60026152D1 (de) Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs
EP1648910A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF STEAROYL COA DESATURASE
DE60027127D1 (de) Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen
ATE253930T1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)- aktivierungsweges
EP1144690A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF A CELLULAR APOPTOSIS-2 INHIBITOR
EP1163373A4 (en) ANTISENSE MODULATION OF THE CELLULAR INHIBITANT OF THE APOPTOSIS EXPRESSION
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
AU2606000A (en) Antisense modulation of x-linked inhibitor of apoptosis expression
ATE271881T1 (de) Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
DE69829316D1 (de) Behandlung des harnblasenkrebses durch mycobacterium phlei zellwand
ATE345121T1 (de) Verwendung von konjugierter linolsäure zur behandlung der erkältung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties